GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
动量输入(同类管理人):
持有人广度 -5.0% ·
股份流向 +4.0% ·
净新建仓位 -5.3%
· 公式
集中增持:持股数量上升,持有人数量减少
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | −1 |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 12.17M | n/a | $633.22M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (被动) | 10.98M | n/a | $571.37M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | Baillie Gifford ✦ | 4.81M | -5.0% | $250.30M | 0.2% | ▼ Trim | 5 | SEC ↗ ×4 |
| 4 | Citadel Advisors ✦ | 2.94M | -18.3% | $152.92M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (被动) | 2.92M | +0.5% | $152.01M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (被动) | 2.84M | +1.4% | $147.78M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | ARK Investment Management ✦ | 2.82M | +100.4% | $146.93M | 1.1% | ▲ Add | 5 | SEC ↗ |
| 8 | Millennium Management ✦ | 2.72M | +148.2% | $141.65M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.92M | -3.6% | $100.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 1.85M | +1.6% | $96.51M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 1.77M | +180.5% | $91.88M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | Norges Bank ✦ (被动) | 1.23M | +1.6% | $64.14M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 987.67K | n/a | $51.40M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 14 | Renaissance Technologies ✦ | 675.20K | +9.5% | $35.14M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 307.31K | -63.7% | $15.99M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 80.13K | +12.0% | $4.17M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 17 | PRIMECAP Management ✦ | 65.99K | +51.1% | $3.43M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | Point72 Asset Management ✦ | 56.30K | -92.8% | $2.93M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 3.87K | -23.7% | $201,395 | 0.0% | ▼ Trim | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Marshall Wace | $7.52M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 481 持有人, 137.05M 股份, $11.53B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Director · 116 股 · $19,242
Director · 69 股 · $11,032
Director · 1.10K 股 · $192,432
Director · 826 股 · $144,550
Director · 3.30K 股 · $578,888
Director · 1.30K 股 · $229,236
Director · 971 股 · $172,330
Director · 116 股 · $20,300
Officer · 7.74K 股 · $1.38M
Officer · 4.00K 股 · $632,193
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论